December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Extended Market ETF (NY:VXF)

214.51 -0.28 (-0.13%)
Streaming Delayed Price Updated: 2:52 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Extended Market ETF

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
The transaction is expected to close in early 2026, provided it receives all required approvals. 
Via Stocktwits
News headline image
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗
The meeting with the FDA is scheduled for January 2026. 
Via Stocktwits
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition ↗
Via Stocktwits
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy ↗
Via Stocktwits
News headline image
Why Is Retail Going Gaga Over INTS Stocks Today? ↗
The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months. 
Via Stocktwits
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗
Via Stocktwits
Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation ↗
Via Stocktwits
Why Did Veritone Stock Fall 17% Today? ↗
Via Stocktwits
News headline image
Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options ↗
The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, Sensei said. 
Via Stocktwits
Topics Workforce
News headline image
ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials ↗
The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 
Via Stocktwits
News headline image
Intelligent Bio Solutions Stock Rises On New Contract For Drug Testing Technology ↗
The new customer account represents one of INBS's most significant UK commercial deployments to date, the company said. 
Via Stocktwits
Topics Cannabis
Cyngn Stock Eyes Third Day Of Gains: What's Driving The Buzz? ↗
Via Stocktwits
Micro-Cap Emerson Radio Stock Surges By Two-Thirds In 2 Days, And Then Some More, Piquing Retail Traders ↗
Via Stocktwits
Why Is Fortress Biotech Stock Falling Today? ↗
Via Stocktwits
Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments ↗
Via Stocktwits
GUTS Stock Rallied About 28% Today – Here’s Why ↗
Via Stocktwits
bioAffinity Technologies Stock Surged A Whopping 56% Today – Here’s An Important Update ↗
Via Stocktwits
News headline image
GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious ↗
Galecto is focused on developing treatments for oncological and liver diseases. 
Via Stocktwits
News headline image
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why ↗
The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. 
Via Stocktwits
Topics Intellectual Property
News headline image
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened ↗
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving... 
Via Stocktwits
Topics Workforce
News headline image
Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug ↗
In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis. 
Via Stocktwits
Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside ↗
Via Stocktwits
TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing ↗
Via Stocktwits
Why Did NanoVibronix Stock Jump A Whopping 74% Today? ↗
Via Stocktwits
Helius Medical Stock Rockets 169% After Company Raises $500M To Make Solana Its Primary Treasury Asset: Retail Cheers The Deal ↗
Via Stocktwits
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study ↗
Via Stocktwits
News headline image
Robinhood Draws Wall Street Praise Over Launch Of New Social Media Platform At HOOD Summit – More Details Inside ↗
Barclays analyst Benjamin Budish noted that Robinhood is accelerating the rollout of features, describing the updates as modern and user-friendly. 
Via Stocktwits
Topics Artificial Intelligence Economy
Professional Diversity Network Stock Exploded Over 400% Today – Here’s An Update ↗
Via Stocktwits
BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later ↗
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.